A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.
Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin
DRUG: SGN-35|DRUG: gemcitabine
Incidence of adverse events and laboratory abnormalities, 1 month after last dose
PK profile, 2 months after last dose|Immunogenicity (anti-SGN-35 antibodies), 1 month after last dose|Anti-tumor activity, 1 month after last dose
This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.